Annals of Medicine (Dec 2024)

Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience

  • Pierachille Santus,
  • Marina Saad,
  • Anna Casartelli,
  • Rosaria Lorusso,
  • Lisa Milani,
  • Fiammetta Danzo,
  • Paolo Busatto,
  • Dejan Radovanovic

DOI
https://doi.org/10.1080/07853890.2024.2407523
Journal volume & issue
Vol. 56, no. 1

Abstract

Read online

Background Patients with severe asthma frequently have comorbid chronic rhinosinusitis (CRS) with or without nasal polyps, that can increase the symptom burden and complicate treatment. Real-life clinical data on the impact of biologic treatments on CRS-specific quality-of-life questionnaires are still lacking.Materials and methods In this retrospective real-life study, we collected data from patients with severe asthma with comorbid CRS with/without nasal polyposis at baseline, and after 3, 6 and 12 months of treatment with omalizumab, mepolizumab, benralizumab or dupilumab. In particular, we evaluated improvements in HRQoL as measured by SinoNasal Outcome Test‐22 (SNOT‐22, 0 – 110), Visual Analog Scale symptom scores (VAS, 0–10), and Asthma Control Test (ACT, 5–25) and the proportion of patients meeting the minimal clinically important difference (MCID).Results Disease-specific HRQoL, as measured by SNOT 22 and VAS score improved in all patients at 3, 6, and 12 months of treatment compared with baseline (SNOT-22: 14, IQR: 0–52 vs 10, IQR:0–30 vs 0, IQR:0–15 vs 0, IQR:0–12, p 80% of patients reached the MCID for ACT, while only patients on dupilumab showed to reach a MCID in 100% of cases. The effect size depended upon the symptom burden at baseline.Conclusions The study confirms the efficacy of omalizumab, mepolizumab, benralizumab, and dupilumab in a real-life setting, with a rapid improvement in CRS-specific HRQoL and general health status. These data highlight the importance of targeting type 2 inflammation in asthmatic patients with co-existing upper and lower airways disease.The Authors disclose that preliminary data and analysis of the present study have been presented in abstract form during the “X International Workshop on Lung Health – Respiratory Disease and Immune Response”, held in Nice on 19–21 January 2023.

Keywords